LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Listă Acțiuni・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Închisă

3.79 3.84

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

3.66

Maxim

3.89

Indicatori cheie
By Trading Economics
Venit	-511K -28M
Vânzări	-13M 2.6M
EPS	-0.47
Marjă de profit	-1,077.401
Angajați	141
EBITDA	-455K -29M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+311.41% upside

Dividende
By Dow Jones
Următoarele câștiguri	4 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-23M 212M
Deschiderea anterioară	-0.05
Închiderea anterioară	3.79

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

3.17 / 3.4644 Suport & Rezistență

Voyager Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

22 mai 2026, 16:33 UTC

Câștiguri

Principalele dinamici ale pieței

Webull Shares Slide on 1Q Loss, Soaring Costs

22 mai 2026, 21:10 UTC

Câștiguri

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22 mai 2026, 20:50 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Financial Services Roundup: Market Talk

22 mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

22 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22 mai 2026, 19:47 UTC

Câștiguri

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 mai 2026, 19:17 UTC

Market Talk

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 mai 2026, 19:10 UTC

Market Talk

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 mai 2026, 18:54 UTC

Market Talk

Global Equities Roundup: Market Talk

22 mai 2026, 18:54 UTC

Market Talk

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 mai 2026, 18:38 UTC

Market Talk

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 mai 2026, 18:35 UTC

Achiziții, Fuziuni, Preluări

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 mai 2026, 18:09 UTC

Market Talk

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 mai 2026, 17:58 UTC

Market Talk

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

22 mai 2026, 17:54 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

22 mai 2026, 17:54 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22 mai 2026, 17:54 UTC

Market Talk

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

22 mai 2026, 17:03 UTC

Market Talk

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

22 mai 2026, 16:54 UTC

Market Talk

Crypto Spot Volumes Fall 14% in April -- Market Talk

22 mai 2026, 16:20 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Financial Services Roundup: Market Talk

22 mai 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

22 mai 2026, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

22 mai 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

22 mai 2026, 16:16 UTC

Market Talk

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

22 mai 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

22 mai 2026, 15:55 UTC

Market Talk

Trump Admin Grants Reinforce IBM's Quantum Computing Leadership -- Market Talk

22 mai 2026, 15:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22 mai 2026, 15:42 UTC

Market Talk

Oil Continues as Leading Indicator for All Markets -- Market Talk

22 mai 2026, 15:35 UTC

Market Talk

Gas Prices May Limit Spread of Inflationary Pressures in Canada -- Market Talk

Comparație

Modificare preț

Voyager Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

311.41% sus

Prognoză pe 12 luni

Medie 15.14 USD 311.41%

Maxim 25 USD

Minim 8 USD

În baza a 9 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruVoyager Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

9 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 9 analiști care au acordat evaluări ale acțiunilor Voyager Therapeutics Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

3.17 / 3.4644Suport & Rezistență

Recent bearish events outweigh bullish events.

All events are bearish.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.